m&a – Duane Morris Life Sciences Law

In a recent GEN Edge article, Duane Morris partner Rebecca Guzman discussed the state of M&A activity in the life sciences.

“Following the most robust year for life sciences M&A on record, the sector saw a sharp decline in 2022 to levels below what we last experienced pre-pandemic. Many analysts pointed to supply chain issues, clinical development delays and other lingering effects of the COVID-19 pandemic as the cause. The 2021 catalysts of innovation following the pandemic breakout had finally worn off. On the surface, it appeared that key industry players had taken a step back, or even hit pause, but continued background activity tells a different story. While deal flow declined, the underlying drivers of M&A activity throughout 2022 (and continuing through today) remain strong.”

Read the full article at genengnews.com.

Duane Morris’ Life Sciences and Medical Technologies Industry Group has been ranked in The Legal 500 US 2021 guide.

An excerpt from the publication:

Duane Morris LLP is recommended for its expertise in M&A, patents, and commercial licensing and collaboration agreements, acting for domestic companies in addition to a strong roster of clients in the Asia-Pacific region.

Testimonials

- - - “They understand client’s needs and work very closely to address those. Team has subject knowledge and applies it effectively in strategizing pre-litigation and litigation matters.”
    - “They suggest different strategies and ideas for defenses. Also, innovative ways for settlement terms. Billing is also great and adjusts according to client’s needs.”
    - “Rick Ball is the individual who stands out. He gels with client’s team very well, understands their needs, flexible, innovative, strategizes properly.”